Latest Intellectual Property News

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) has received FDA Investigational New Drug clearance to initiate a pivotal clinical trial of its cell therapy Ryoncil in children with Duchenne Muscular Dystrophy, aiming to address inflammation-driven disease progression.

Argent Minerals (ASX: ARD) has announced Managing Director Pedro Kastellorizos will step down in mid-June, with a leadership transition underway. The company remains focused on advancing its Kempfield Silver Project and exploration activities.

Temas Resources Corp has appointed chemical process expert Dr. Santiago Faucher to its Scientific Advisory Board, enhancing the technical and commercialisation capabilities of its Regenerative Chloride Leaching (RCL) technology. This move supports the company’s strategy to advance its innovative hydrometallurgical platform and complements its mineral project developments in Québec.

Archer Materials has progressed its Biochip program by completing the alpha prototype and Stage 1 project with IMEC, now advancing to develop a beta prototype suitable for external use and clinical validation.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.

Environmental Clean Technologies Limited (ASX: ECT) has broadened its licence with Rice University to apply Flash Joule Heating technology to PFAS-contaminated adsorbents like granular activated carbon, complementing its existing soil remediation platform.

Pure Resources Limited has entered a legally binding R&D collaboration with Rice University to develop cutting-edge carbon nanotube fibre thermal management systems using graphite from its Garnet Hills Project. The partnership includes joint intellectual property ownership and a planned $3 million equity placement to fund exploration and downstream initiatives.

Pure Resources has launched a cutting-edge research collaboration with Rice University to develop carbon nanotube fibre thermal management systems, leveraging graphite from its Garnet Hills Project. The initiative is backed by a $3 million equity raise to fund exploration and downstream material innovation.

Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.

Genetic Technologies Limited remains under voluntary administration while progressing a Deed of Company Arrangement and has completed the sale of its geneType business, ending the quarter with $270,000 in cash.

Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.

BrainChip Holdings has inked a global licensing agreement with Korea’s EDGEAI, granting access to its Akida 2 neuromorphic AI technology for EDGEAI’s upcoming semiconductor products. The deal includes milestone payments and royalties, marking a significant step in BrainChip’s global expansion and the growing edge AI market.